Evolving Research Paradigms, Real-World Data, and Multidisciplinary Collaboration Enhance Bladder Cancer Management: With Amit Mehta, MD

Dr Mehta discussed practice-changing urothelial carcinoma data that have been presented throughout 2024 and 2025, the clinical utility of enfortumab vedotin plus pembrolizumab for select patients with advanced or metastatic urothelial cancer, and differing treatment approaches for patients with lymph node–only vs distant metastases.